Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
基本信息
- 批准号:6797384
- 负责人:
- 金额:$ 99.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-09-26 至 2006-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Cellulose acetate phthalate (CAP) has
been used as an enteric film coating material or as a matrix binder for
tablets and capsules. It is widely used in oral pharmaceutical products and
is generally regarded as a nontoxic material free of adverse effects. It is
included in the FDA Inactive Ingredients Guide and is listed in pharmacopoeias
internationally. CAP is available in large quantities and is inexpensive. It
was demonstrated that CAP: 1) has antiviral activity against HIV-1 and several
herpesviruses (HSV); and 2) when formulated in a micronized form a)
inactivated in vitro HIV-1, HSV-1. HSV-2, cytomegalovirus, Neisseria
gonorrhoeae, Trichomonas vaginalis, Haemophilus ducreyi and Chlamydia
trachomatis; b) inactivated bacteria associated with bacterial vaginosis; c)
protected mice against vaginal infection by HSV-2; and d) protected 4/6 rhesus
monkeys from vaginal infection with simian immunodeficiency virus (SIVmac251).
These results have established the promise of CAP as a microbicide for
prevention of sexual transmission of HIV-1. Additional preclinical studies are
needed to further support this promise. This includes: (Project I): Prevention
of infection by primary HIV-1 isolates and distinct HIV-1 clades in cell
cultures in vitro and in human cervical and rectal tissue models; (Project
II): a) Assess the safety of CAP in a monkey model by colposcopic examinations
and measurement of pro-inflammatory chemokines and cytokines; b) Assessment of
CAP distribution after vaginal application in monkeys using chemically tagged
CAP and colposcopy, and magnetic resonance imaging (MRI); and c) Evaluate the
efficacy of CAP against infection with pathogenic X4- and R5-specific
simian/human chimeric HIV viruses (SHIV), respectively; (Project III):
Measurement of pro-inflammatory chemokines and cytokines after exposure of
cervical and vaginal epithelial cells in culture to CAP; (Project IV): Studies
on CAP-human sperm interactions to assess the spermicidal/contraceptive
potential of CAP and its formulations. Information gained from the proposed
studies, coordinated and supplied by uniform and quality controlled
formulations by Cores A, B, respectively, is expected to facilitate the design
of Phase I, II and III human clinical trials. CAP meets criteria proposed for
an ideal microbicide: activity in presence of semen and blood; activity
against sexually transmitted infections other than HIV-1; condom
compatibility, negligible systemic absorption (due to its large, molecular
mass and micronized state); lack of color and unpleasant taste; and low cost.
The proposed research is expected to help transform this ideal into a reality.
说明(申请人提供):邻苯二甲酸纤维素(CAP)
用作肠溶膜包衣材料或作为基质粘合剂
片剂和胶囊。它广泛应用于口腔医药产品和
通常被认为是一种无毒、无不良影响的物质。它是
包括在FDA非活性成分指南中,并列在药典中
在国际上。帽子有大量供应,而且价格不贵。它
证明CAP:1)具有抗HIV-1和几种
疱疹病毒(HSV);和2)以微粉化形式配制时)
体外灭活HIV-1、HSV-1。单纯疱疹病毒2型、巨细胞病毒、奈瑟氏菌
淋病、阴道毛滴虫、杜热氏嗜血杆菌和衣原体
沙眼衣原体;b)与细菌性阴道病有关的灭活细菌;c)
保护小鼠免受HSV-2的阴道感染;和d)保护4/6的恒河猴
猴子阴道感染猴免疫缺陷病毒(SIVmac251)。
这些结果为CAP作为一种杀菌剂的前景奠定了基础
预防艾滋病毒-1的性传播。其他临床前研究包括
需要进一步支持这一承诺。这包括:(项目一):预防
由HIV-1初级分离株和细胞内不同的HIV-1分支感染
体外培养和人类宫颈和直肠组织模型;(项目
二):a)通过镜检查评估CAP在猴子模型中的安全性
以及促炎趋化因子和细胞因子的测定;b)评估
化学标记法在猴阴道给药后的帽子分布
帽和阴道镜检查以及核磁共振成像(MRI);以及c)评估
CAP对致病性X4和R5特异性感染的疗效
猴/人嵌合艾滋病毒病毒(SIV);(项目三):
暴露后致炎趋化因子和细胞因子的检测
宫颈和阴道上皮细胞对CAP的培养;(项目IV):研究
CAP与人精子相互作用评价杀精/避孕效果的研究
CAP及其制剂的潜力。从建议的
学习,统一协调,统一供应,质量控制
由岩芯A、B分别配制的配方有望促进设计
一期、二期和三期人体临床试验。上限符合建议的标准
一种理想的杀微生物剂:在精液和血液存在下的活性
预防艾滋病毒-1以外的性传播感染;避孕套
兼容性,可忽略的系统吸收(由于其大的分子
大批量和微粉化);缺乏颜色和难吃的味道;以及低成本。
这项拟议的研究有望帮助将这一理想转变为现实。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Guiding the vaginal microbicide trials with biomarkers of inflammation
- DOI:10.1097/00126334-200410013-00010
- 发表时间:2004-10-01
- 期刊:
- 影响因子:3.6
- 作者:Fichorova, RN
- 通讯作者:Fichorova, RN
Anti-HIV-1 activity of poly(mandelic acid) derivatives.
- DOI:10.1021/bm070221y
- 发表时间:2007-10
- 期刊:
- 影响因子:6.2
- 作者:Marty Ward;Bing Yu;V. Wyatt;Jelani Griffith;Tara L. Craft;A. Neurath;N. Strick;Yun-yao Li;D. Wertz;J. Pojman;A. Lowe
- 通讯作者:Marty Ward;Bing Yu;V. Wyatt;Jelani Griffith;Tara L. Craft;A. Neurath;N. Strick;Yun-yao Li;D. Wertz;J. Pojman;A. Lowe
Safety and distribution of cellulose acetate 1,2-benzenedicarboxylate (CAP), a candidate anti-HIV microbicide in rhesus macaques.
醋酸纤维素 1,2-苯二甲酸 (CAP) 的安全性和分布,它是一种候选抗 HIV 杀菌剂,在恒河猴中使用。
- DOI:10.1097/01.aids.0000185990.16477.47
- 发表时间:2005
- 期刊:
- 影响因子:0
- 作者:Ratterree,Marion;Gettie,Agegnehu;Williams,Victoria;Malenbaum,Susan;Neurath,ARobert;Cheng-Mayer,Cecilia;Blanchard,James
- 通讯作者:Blanchard,James
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
A ROBERT ROBERT NEURATH其他文献
A ROBERT ROBERT NEURATH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('A ROBERT ROBERT NEURATH', 18)}}的其他基金
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film
抗HIV-1复合醋酸纤维素邻苯二甲酸酯薄膜
- 批准号:
6803829 - 财政年份:2004
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV-1 Composite Cellulose Acetate Phthalate Film
抗HIV-1复合醋酸纤维素邻苯二甲酸酯薄膜
- 批准号:
6953768 - 财政年份:2004
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
- 批准号:
6608543 - 财政年份:2001
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
- 批准号:
6443010 - 财政年份:2001
- 资助金额:
$ 99.75万 - 项目类别:
Anti-HIV Microbicide: Cellulose Acetate Phthalate (CAP)
抗 HIV 杀菌剂:邻苯二甲酸醋酸纤维素 (CAP)
- 批准号:
6526238 - 财政年份:2001
- 资助金额:
$ 99.75万 - 项目类别:
HIV-1 PG120 V3 LOOP TARGETING--NOVEL POTENTIAL INHIBITOR
HIV-1 PG120 V3 环靶向——新型潜在抑制剂
- 批准号:
2460748 - 财政年份:1996
- 资助金额:
$ 99.75万 - 项目类别:
HIV-1 PG120 V3 LOOP TARGETING--NOVEL POTENTIAL INHIBITOR
HIV-1 PG120 V3 环靶向——新型潜在抑制剂
- 批准号:
2292288 - 财政年份:1996
- 资助金额:
$ 99.75万 - 项目类别:
HIV-1 PG120 V3 LOOP TARGETING--NOVEL POTENTIAL INHIBITOR
HIV-1 PG120 V3 环靶向——新型潜在抑制剂
- 批准号:
2751045 - 财政年份:1996
- 资助金额:
$ 99.75万 - 项目类别:
相似海外基金
Effects of per- and polyfluoroalkyl substances on placental features and size at birth
全氟烷基和多氟烷基物质对出生时胎盘特征和大小的影响
- 批准号:
10645524 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy
醋酸鲁沙来肽 (TP508) 对放射诱发的角膜病变的缓解作用
- 批准号:
10605739 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Gut microbiota metabolite sensing licenses IEC to cross talk with T cells to inhibit intestinal inflammation
肠道微生物代谢传感许可 IEC 与 T 细胞交互作用以抑制肠道炎症
- 批准号:
10602998 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10573109 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10818835 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Prenatal Cigarette Smoke Exposure: Impact on Offspring Gut Bacterial Microbiome
产前香烟烟雾暴露:对后代肠道细菌微生物组的影响
- 批准号:
10747173 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
MECHANISMS OF VISCERAL PAIN DRIVEN BY SMALL INTESTINAL MICROBIOTA
小肠微生物驱动内脏疼痛的机制
- 批准号:
10836298 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别:
Evaluating the Mechanisms of Afferent Renal Nerve Ablation as a Treatment for Hypertension
评估传入肾神经消融治疗高血压的机制
- 批准号:
10604700 - 财政年份:2023
- 资助金额:
$ 99.75万 - 项目类别: